Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
The closing price of Atyr Pharma Inc (NASDAQ: ATYR) was $5.07 for the day, up 0.80% from the previous closing price of $5.03. In other words, the price has increased by $0.80 from its previous closing price. On the day, 4.09 million shares were traded. ATYR stock price reached its highest trading level at $5.35 during the session, while it also had its lowest trading level at $4.98.
Ratios:
Our analysis of ATYR’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 7.79 and its Current Ratio is at 7.79. In the meantime, Its Debt-to-Equity ratio is 0.17 whereas as Long-Term Debt/Eq ratio is at 0.16.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Leerink Partners on February 18, 2025, initiated with a Outperform rating and assigned the stock a target price of $16.
On October 04, 2024, Wells Fargo started tracking the stock assigning a Overweight rating and target price of $17.Wells Fargo initiated its Overweight rating on October 04, 2024, with a $17 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Mar 17 ’25 when Gross Jane A bought 3,750 shares for $4.00 per share. The transaction valued at 15,000 led to the insider holds 9,750 shares of the business.
Broadfoot Jill Marie sold 1,254 shares of ATYR for $4,740 on Feb 04 ’25. The Chief Financial Officer now owns 31,763 shares after completing the transaction at $3.78 per share. On Feb 04 ’25, another insider, DENYES NANCY, who serves as the General Counsel of the company, sold 899 shares for $3.78 each. As a result, the insider received 3,398 and left with 26,555 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ATYR now has a Market Capitalization of 451252320 and an Enterprise Value of 387705504.
Stock Price History:
The Beta on a monthly basis for ATYR is 0.89, which has changed by 2.3355262 over the last 52 weeks, in comparison to a change of 0.12632763 over the same period for the S&P500. Over the past 52 weeks, ATYR has reached a high of $5.98, while it has fallen to a 52-week low of $1.48. The 50-Day Moving Average of the stock is 21.00%, while the 200-Day Moving Average is calculated to be 48.71%.
Shares Statistics:
ATYR traded an average of 2.04M shares per day over the past three months and 4219760 shares per day over the past ten days. A total of 89.00M shares are outstanding, with a floating share count of 86.06M. Insiders hold about 3.31% of the company’s shares, while institutions hold 68.54% stake in the company. Shares short for ATYR as of 1749772800 were 13644953 with a Short Ratio of 6.68, compared to 1747267200 on 12681301. Therefore, it implies a Short% of Shares Outstanding of 13644953 and a Short% of Float of 18.709999999999997.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The dynamic stock of Atyr Pharma Inc (ATYR) is currently attracting attention from 11.0 analysts actively involved in rating its market status.The consensus estimate for the next quarter is -$0.15, with high estimates of -$0.04 and low estimates of -$0.21.
Analysts are recommending an EPS of between -$0.01 and -$0.79 for the fiscal current year, implying an average EPS of -$0.61. EPS for the following year is -$0.61, with 11.0 analysts recommending between $0.27 and -$1.29.
